Entries by Phil Case

AnPac Bio Announces Appointment of New Independent Director Independent Director has Strong Track Record at US Fortune 500 Companies

AnPac Bio Announces Appointment of New Independent Director Independent Director has Strong Track Record at US Fortune 500 Companies Philadelphia, Pennsylvania, July 23, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that Mr. Chao Feng, […]

AnPac Bio Began Generating Contract Medical Device R&D Revenue Also in Final Stages of Partnership/Cooperation Discussions with Major Corporations

FOR IMMEDIATE RELEASE AnPac Bio Enters into Contract with Cancer Treatment Company JV Partner Philadelphia, Pennsylvania, July 21, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it […]

AnPac Bio Pre-announces that During First Half 2021, Total Commercial Testing Volume Increased Approximately 110% Over the Same Period 2020 and Q2 Paid Cancer Tests Increased Approximately 270% Over Q1

FOR IMMEDIATE RELEASE AnPac Bio Pre-announces that During First Half 2021, Total Commercial Testing Volume Increased Approximately 110% Over the Same Period 2020 and Q2 Paid Cancer Tests Increased Approximately 270% Over Q1 Philadelphia, Pennsylvania, July 20, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company […]

AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds

FOR IMMEDIATE RELEASE AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds Philadelphia, Pennsylvania, June 18, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and […]

AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests Completed

AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests Completed Philadelphia, Pennsylvania, May 27, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its […]

AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture – Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database

AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture – Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database  San Jose, CA, May 24, 2021 – AnPac Bio-Medical Science Co., Ltd. (ANPC) (“AnPac Bio,” the “Company” or “we”), a biotechnology company with operations in China and the […]

AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020

AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020 FOR IMMEDIATE RELEASE San Jose, CA., April 30, 2021—AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has […]

AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss)

AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss) SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its […]

AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020

FOR IMMEDIATE RELEASE AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020 San Jose, CA, April 16, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused […]

©2021 Anpac Bio-Medical Science Co., Ltd.